BNF August 2022 Update

This update contains 4 significant changes, 3 dose changes, 5 new monographs and 2 new preparations.

Significant Changes:

• Meropenem with vaborbactam [update to how dose is expressed].
• Metformin hydrochloride: reduced vitamin B12 levels and new advice for monitoring patients at risk [MHRA/CHM advice].
• Type 1 diabetes: inclusion of continuous glucose monitoring in aims of treatment.
• Type 2 diabetes: updated guidance for the use of non-insulin antidiabetic drugs.

Dose Changes:

• Cyanocobalamin [update to indications and dose].
• Empagliflozin [update to indication and dose (age ranges and heart failure indication amended), and advice on use and dosing in renal impairment].
• Sotrovimab [update to indications and dose to remove body-weight from dose statement].

New Monographs:

• Bylvay® [odevixibat].
• Ducressa® [dexamethasone with levofloxacin].
• Gavreto® [pralsetinib].
• Vabysmo® [faricimab].
• Xerava® [eravacycline].

New Preparations: Orobalin® [cyanocobalamin]; Uxil® [dasatinib].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699